111 related articles for article (PubMed ID: 12402499)
1. CDKs and CKIs: molecular targets for tissue remodelling.
Nabel EG
Nat Rev Drug Discov; 2002 Aug; 1(8):587-98. PubMed ID: 12402499
[TBL] [Abstract][Full Text] [Related]
2. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential.
Andrés V
Cardiovasc Res; 2004 Jul; 63(1):11-21. PubMed ID: 15194457
[TBL] [Abstract][Full Text] [Related]
3. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
4. The cell cycle and cardiovascular diseases.
Boehm M; Nabel EG
Prog Cell Cycle Res; 2003; 5():19-30. PubMed ID: 14593697
[TBL] [Abstract][Full Text] [Related]
5. Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development.
Nakayama K; Nakayama K
Bioessays; 1998 Dec; 20(12):1020-9. PubMed ID: 10048302
[TBL] [Abstract][Full Text] [Related]
6. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
[TBL] [Abstract][Full Text] [Related]
7. Cyclin dependent kinase inhibitors.
Harper JW
Cancer Surv; 1997; 29():91-107. PubMed ID: 9338098
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs).
Graña X; Reddy EP
Oncogene; 1995 Jul; 11(2):211-9. PubMed ID: 7624138
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase inhibitors.
Fischer PM; Endicott J; Meijer L
Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease.
Ivorra C; Samyn H; Edo MD; Castro C; Sanz-González SM; Déez-Juan A; Andrés V
Curr Pharm Biotechnol; 2003 Feb; 4(1):21-37. PubMed ID: 12570680
[TBL] [Abstract][Full Text] [Related]
11. [Cyclin-dependent kinase inhibitors in mammal cells].
Jiang H; Wang YC
Sheng Li Ke Xue Jin Zhan; 1996 Apr; 27(2):107-12. PubMed ID: 9592231
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors?
Besson A; Assoian RK; Roberts JM
Nat Rev Cancer; 2004 Dec; 4(12):948-55. PubMed ID: 15573116
[TBL] [Abstract][Full Text] [Related]
13. CDK inhibitors in cancer therapy: what is next?
Malumbres M; Pevarello P; Barbacid M; Bischoff JR
Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
[TBL] [Abstract][Full Text] [Related]
14. Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin.
Rodriguez-Puebla ML; LaCava M; Gimenez-Conti IB; Johnson DG; Conti CJ
Oncogene; 1998 Oct; 17(17):2251-8. PubMed ID: 9811455
[TBL] [Abstract][Full Text] [Related]
15. p27: a pleiotropic regulator of cellular phenotype and a target for cell cycle dysregulation in cancer.
Desdouets C; Bréchot C
Pathol Biol (Paris); 2000 Apr; 48(3):203-10. PubMed ID: 10858954
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases.
Wang H; Shao N; Ding QM; Cui J; Reddy ES; Rao VN
Oncogene; 1997 Jul; 15(2):143-57. PubMed ID: 9244350
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
Kaubisch A; Schwartz GK
Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
[TBL] [Abstract][Full Text] [Related]
18. Whether to target single or multiple CDKs for therapy? That is the question.
Węsierska-Gądek J; Maurer M; Zulehner N; Komina O
J Cell Physiol; 2011 Feb; 226(2):341-9. PubMed ID: 20836132
[TBL] [Abstract][Full Text] [Related]
19. Non-CDK-bound p27 (p27(NCDK)) is a marker for cell stress and is regulated through the Akt/PKB and AMPK-kinase pathways.
Björklund MA; Vaahtomeri K; Peltonen K; Viollet B; Mäkelä TP; Band AM; Laiho M
Exp Cell Res; 2010 Mar; 316(5):762-74. PubMed ID: 20036235
[TBL] [Abstract][Full Text] [Related]
20. Persistent and heterogenous expression of the cyclin-dependent kinase inhibitor, p27KIP1, in rat hearts during development.
Koh KN; Kang MJ; Frith-Terhune A; Park SK; Kim I; Lee CO; Koh GY
J Mol Cell Cardiol; 1998 Mar; 30(3):463-74. PubMed ID: 9515024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
